Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

Table 5 Results for all participants recruited outside the pollen season

N users Day 1	Treatment days				No treatment days	P value*
	FF	MPAzeFlu	MF	OAH mono
	99	80	95	275	1299
Symptoms day 1
Runny nose (%)	72	55	65	71	65	0.03
Itchy nose (%)	72	53	61	61	53	0.03
Sneezing (%)	76	49	71	74	67	<0.001
Nasal congestion (%)	84	63	78	65	62	0.001
Red eyes (%)	39	21	38	41	36	0.006
Itchy eyes (%)	55	38	47	62	52	0.04
Watery eyes (%)	41	29	27	45	34	0.35
Impact of symptoms day 1
Sleep (%)	47	36	43	35	32	0.17
Daily activities (%)	46	36	34	37	38	0.54
Work/school (%)	30	31	24	25	24	0.51
Bothersome (%)	84	55	68	67	67	<0.001
ARIA score (%)
0	8	22	19	20	23
1	30	38	29	34	31
2	23	16	22	21	21	0.06
3	22	10	22	12	15
4	16	14	7	13	11
Median [p25-75]	2 [1–3]	1 [1–2]	2 [1–3]	1 [1–3]	1 [0–2]	0.04
VAS global day 1 (%)
N	99	80	95	275	1299
<20	25	29	27	27	41	0.68
20-49	28	34	33	31	29
≥50	46	38	40	42	30
Median [p25-75]	44 [19–67]	34.5 [15–62.5]	46 [17–64]	38 [18–66]	29 [6–54]	0.25
VAS global – all days (%)
N days	1116	1258	1437	1956	13,120
N users	167	128	154	437	1553
Average number of days per user^±	6.7	9.8	9.3	4.5	8.5
<20	50	54	59	50	74	0.0001
20-49	29	33	27	27	16
≥50	21	13	15	23	10
Median [p25-75]	19 [5.5-44]	18 [7–36]	14 [5–34]	19 [5-47]	5 [0-20]	0.18

FF Fluticasone Furoate, MF Mometasone Furoate, MPAzeFlu Azelastine-Fluticasone Propionate
* Comparing MPAzeFlu versus FF or MF. Chi square tests were used for categorical variables (i.e. symptoms and impact of symptoms, ARIA score, global VAS categories); Kruskal–Wallis tests were used for continuous variables (i.e. ARIA score, global VAS)
^± Estimated by dividing the total number of days for which the use of a medication was reported by the total number of users reporting that medication
p25: 25th percentile; p75: 75th percentile

ISSN: 2045-7022